Atherosclerosis Market
Atherosclerosis Treatment to gain traction amid rising Cardiac Ailment Incidences and associated co-morbidities
Atherosclerosis Market by Therapy, Surgery, Distribution Channel & Region - Forecast 2022 – 2032
Atherosclerosis Market Snapshot (2022-2032)
[301 Pages Report] The atherosclerosis market is anticipated to attain a valuation of US$ 58,236.4 Million by 2032, growing at a CAGR of 2.8% between 2022 and 2032, from a current value of US$ 44,183.8 Million in 2022. The rise in the prevalence of cardiovascular disorders is a significant factor driving market growth.
|
Data Points |
Key Statistics |
|
Expected Market Value (2022) |
US$ 44,183.8 Million |
|
Anticipated Forecast Value (2032) |
US$ 58,236.4 Million |
|
Projected Growth Rate (2022-2032) |
2.8% CAGR |
Atherosclerosis is the shrinking of a vein caused by plaque accumulation. Atherosclerosis is a kind of arteriosclerosis (stiffening or solidifying of the artery walls). The sickness disrupts the flow of blood throughout the body, posing significant cardiovascular complications.
Atherosclerosis starts when the endothelium is damaged, allowing LDL cholesterol to accumulate in the arterial wall. To clean up the cholesterol, the body sends macrophage white platelets.
However, the cells occasionally halt at the impacted spot. After a while, this resulted in the formation of plaque, which was composed of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, disrupting the flow of blood throughout the body. This may result in blood clusters, which can lead to life-threatening diseases such as heart attack, stroke, and other cardiovascular disorders.
Aside from age, the following factors increase the risk of atherosclerosis: high blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and a poor diet.
Atherosclerosis Demand Analysis (2017 To 2021) Vs Market Outlook (2022 To 2032)
The global demand for atherosclerosis treatment is projected to increase at a CAGR of 2.8% during the forecast period between 2022 and 2032, reaching a total of US$ 58,236.4 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 1.9%.
The rising number of heart attacks caused by atherosclerosis or coronary heart disease is expected to drive up demand for atherosclerosis treatment products. The ageing population is expected to drive demand during the forecast period.
According to the CDC (Centres for Disease Control and Prevention), coronary illness accounts for approximately 610,000 deaths per year in the United States, accounting for roughly one out of every four reported deaths. Coronary disease is the most well-known type of coronary disease, killing over 370,000 people each year.
This increase in the baby boomer population is expected to increase the number of atherosclerosis patients and, as a result, demand for treatment over the forecast period.
The market for atherosclerosis is growing due to increased prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, particularly a decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down.
Statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs), and nitrates are among the medications used to treat atherosclerosis.
Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are expected to be launched during the forecasting period.
Which Are Some Prominent Drivers Of Atherosclerosis Market?
An Expanding Geriatric Population base and Subsequent Rise in Cardiac Anomalies
The worldwide atherosclerosis industry is poised to increase as the geriatric population grows and the incidence rate of heart attacks caused by coronary heart disease or atherosclerosis rises. Furthermore, the availability of new treatment approaches (both branded and generic) is a major driver of the global atherosclerosis therapeutics market.
According to the Centres for Disease Control and Prevention (CDC), approximately 610, 000 people in the United States died as a result of heart disease, accounting for nearly one out of every four deaths. Coronary artery disease is the most common type of heart disease, accounting for approximately 370,000 deaths each year. These factors are expected to boost the global market for atherosclerosis.
Increasing Prevalence of Obesity and High Cholesterol to Widen Growth Prospects
Rising obesity and high cholesterol rates are expected to boost market growth by increasing the risk of atherosclerosis. According to the World Health Organization, approximately 40 million children under the age of five were overweight or obese in 2018. (WHO).
Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility as a result of the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanisation, are all contributing to high cholesterol rates, resulting in rapid market growth.
Furthermore, rising awareness-raising initiatives by public and private organisations will expand the atherosclerosis market. Furthermore, the sedentary lifestyle of people, such as high alcohol consumption and smoking addiction, will result in the expansion of the atherosclerosis market. The rising level of disposable income and the high prevalence of high blood pressure are expected to drive the industry's growth rate during the forecast period.
What Are The Challenges Faced By The Atherosclerosis Market?
Absence of Definitive Therapy to Stymie the Market Growth
New competitors in the atherosclerosis market have demonstrated increased adequacy and security profiles, as well as a reduction in CHD risk factors. Atherosclerosis, also known as coronary artery disease, has two treatment options: coronary artery bypass grafting (CABG) and angioplasty.
The CAD death rate is relatively high when compared to other diseases caused by coronary events associated with CAD, such as myocardial infections (MI), angina, and strokes. As a result, the antidote to such situations remains an unexplored area of research and development for pharmaceutical companies seeking to bring breakthrough drugs to market.
However, the absence of definitive therapy, side effects and limited efficacy of current medications, and reliance on symptom-based treatment in certain situations are likely to stymie revenue growth in the atherosclerosis market throughout the forecast period.
Moreover, the high cost of the treatment will stymie the market's growth rate. The atherosclerosis market will be challenged by a lack of skilled professionals and a dearth of healthcare infrastructure in developing economies. Furthermore, strict regulatory policies and a lack of public awareness will restrain and impede market growth during the forecast period.
Region-Wise Insights
How is the North American Atherosclerosis Market Shaping Up?
High Prevalence of Cardiovascular Diseases Creating Opportunities for Atherosclerosis Treatment Providers
The North American atherosclerosis market is slated to acquire a market share of 37% in 2022. The presence of key players, the high prevalence of cardiovascular diseases and atherosclerosis, and established healthcare infrastructure are some of the key factors responsible for the market's large share. Furthermore, beneficial government initiatives and an increase in the number of research collaborations are expected to drive market growth.
Because of supportive healthcare policies, a large number of patients, and a developed healthcare market, the United States have the largest share in this region. Every year, approximately 647,000 Americans die from heart disease, accounting for one in every four deaths.
Every year, the United States spends approximately US$ 219 billion on heart disease. According to statistics, the increasing patient pool and disposable revenue in this country drive regional market growth.
Why is Asia-Pacific considering the Fastest Growing Market for Atherosclerosis?
Increasing Geriatric Population favouring market growth
Asia-Pacific is anticipated to increase during the forecast period of 2022-2032 due to an increasing geriatric population and rising disposable income levels in this region.
Furthermore, the expansion of healthcare infrastructure and rising government initiatives will accelerate the market's growth rate in this region. Thus, Asia-Pacific is expected to hold 25% of market share for Atherosclerosis market in the forecast period 2022-2032.
Category-Wise Insights
Which Therapy Segment is Gaining Traction in the Atherosclerosis Market?
Cholesterol-Lowering Medications to remain most sought after
Statins and fibrates are examples of cholesterol-lowering medications. The segment's dominance is attributed to the rising prevalence of cardiovascular disease, high cholesterol, and obesity worldwide. According to the World Health Organization, 40 million children under the age of five were overweight or obese in 2018.
A higher intake of energy-dense foods high in fat and sugars, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanisation, are factors driving high cholesterol rates and, ultimately, boosting segment growth.
In addition, the approval of new cholesterol-lowering medicines is boosting segment growth. For example, the drugs alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs known as PCSK9 inhibitors, which reduce harmful LDL cholesterol levels by more than 50%. Novel treatment drugs of this type boost segment growth. The growing patient pool and increased approvals of new drugs boost segment growth.
Which Is The Leading Distribution Channel Of Atherosclerosis Market?
Retail Pharmacies Will Continue To Be a Beneficial Distribution Channel
As per Future Market Insights (FMI), the Retail pharmacies segment will become the primary point-of-sale channel for atherosclerosis as they expand to even the most remote locations, making it easier for consumers to present prescriptions and purchase drugs.
Furthermore, retail pharmacists provide more consultative services regarding drug administration routes and potential side effects. Retail pharmacies carry a variety of brands, making them a good place for patients to shop. Hospital pharmacists, on the other hand, operate in a more clinic-oriented manner, having frequent contact with doctors and nurses, and they manage their inventories with only specific brands.
Start-Ups for Atherosclerosis Market
Key startup players in the atherosclerosis market:
- Moderna is a leader in the development of a new class of drugs based on messenger RNA (mRNA). This novel drug platform is based on the discovery that modified mRNA can direct the body's cellular machinery to produce nearly any protein of interest, ranging from native proteins to antibodies and completely novel protein constructs with therapeutic activity both inside and outside of cells.
- Humacyte creates novel human tissue-based investigational products for regenerative medicine and vascular surgery. The company's proprietary technology platform is used to isolate and grow stable, "off-the-shelf" investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
- CardioDx is a Redwood City, California-based cardiovascular genomic diagnostics company. CardioDx creates clinically validated genomic tests to aid in the assessment and tailoring of care for people suffering from cardiovascular disease such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
- Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with high-risk cardiovascular disease.
- Avinger creates precision medical device technology to combat Peripheral Artery Disease and assist patients in keeping their legs.
- Milestone Pharmaceuticals is a pharmaceutical company that develops small molecule therapeutics for the treatment of cardiovascular diseases.
- MyoKardia is a precision medicine company that is discovering, developing, and commercializing targeted therapies for the treatment of serious and underserved rare cardiovascular diseases. Our initial focus is on treating heritable cardiomyopathies, a rare, genetically-driven form of heart failure.
- On the basis of their proprietary AFFITOME technology, AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses. We believe that active immunization can play a significant role in the prevention and treatment of chronic civilization illnesses such as atherosclerosis, diabetes, and neurodegenerative diseases.
- Flow MedTech is a Health Wildcatters portfolio company that is developing an innovative therapy to reduce the risk of stroke in atrial fibrillation patients by preventing clot formation in the left atrial appendage. The company's goal is to design, develop, and commercialize novel catheter-based devices to reduce the risk of stroke.
Market Competition
The market for atherosclerosis is moderately competitive, with several major players. Some of the companies that are currently dominating the market are as follows GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics are some prominent players.
Recent Developments In The Atherosclerosis Market Are
- In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.
- In July 2022, GSK plc announced that its wholly owned subsidiary, GSK Finance (No.3) plc, will repurchase all of its outstanding Exchangeable Senior Notes due 2023 for cash.
- In June 2022, Novartis announced new data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrating that continuous Kesimpta® (ofatumumab) treatment significantly increased the odds of achieving no evidence of disease activity (NEDA-3) versus switching from teriflunomide. These findings were presented at the European Academy of Neurology (EAN) Annual Meeting, which will be held virtually on June 25-28, 2022, in Vienna, Austria.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2022 |
US$ 44,183.8 Million |
|
Market Value in 2032 |
US$ 58,236.4 Million |
|
Growth Rate |
CAGR of 2.8% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled In The Atherosclerosis Industry Survey
Atherosclerosis Market by Therapy:
- Atherosclerosis Medications
- Cholesterol-lowering Medications
- Antiplatelet drugs and Anticoagulants
- Atherosclerosis Beta Blockers
- Diuretics or Water Pills
- Angiotensin Converting Enzyme (Ace) Inhibitors
- Other Atherosclerosis Treatment Therapies
Atherosclerosis Market by Surgery:
- Atherosclerosis Treatment through Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
- Atherosclerosis Treatment through Angioplasty
- Atherosclerosis Treatment through Atherectomy
Atherosclerosis Market by Distribution Channel:
- Atherosclerosis Treatment in Hospitals
- Atherosclerosis Treatment via Pharmacies
- Atherosclerosis Treatment via Drug Stores
- Atherosclerosis Treatment via Retail Pharmacies
- Atherosclerosis Treatment in Clinics
Atherosclerosis Market by Region:
- North America Atherosclerosis Market
- Latin America Atherosclerosis Market
- Europe Atherosclerosis Market
- Asia Pacific Atherosclerosis Market
- Middle East and Africa Atherosclerosis Market
Frequently Asked Questions
FMI projects the global atherosclerosis market to expand at a 2.8% value CAGR by 2032
The global atherosclerosis market is estimated at a market value of US$ 44,183.8 Million
The global atherosclerosis market is expected to garner a market value of US$ 58,236.4 Million
North America is expected to possess 37.0% market share for Atherosclerosis market in the assessment period 2022-2032
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2016-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Therapy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy, 2016-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy, 2022-2032
5.3.1. Medications
5.3.2. Cholesterol-lowering Medications
5.3.3. Antiplatelet Drugs & Anticoagulants
5.3.4. Beta Blockers
5.3.5. Diuretics or Water Pills
5.3.6. Angiotensin Converting Enzyme (ACE) Inhibitors
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Therapy, 2016-2021
5.5. Absolute $ Opportunity Analysis By Therapy, 2022-2032
6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Surgery
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Surgery, 2016-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Surgery, 2022-2032
6.3.1. Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
6.3.2. Angioplasty
6.3.3. Atherectomy
6.4. Y-o-Y Growth Trend Analysis By Surgery, 2016-2021
6.5. Absolute $ Opportunity Analysis By Surgery, 2022-2032
7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2016-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
7.3.1. Hospital Pharmacies
7.3.2. Drug Stores
7.3.3. Retail Pharmacies
7.3.4. Clinics
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2016-2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
8. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. US
9.2.1.2. Canada
9.2.2. By Therapy
9.2.3. By Surgery
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapy
9.3.3. By Surgery
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Therapy
10.2.3. By Surgery
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy
10.3.3. By Surgery
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Therapy
11.2.3. By Surgery
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy
11.3.3. By Surgery
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Therapy
12.2.3. By Surgery
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy
12.3.3. By Surgery
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Therapy
13.2.3. By Surgery
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy
13.3.3. By Surgery
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. US
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Therapy
14.1.2.2. By Surgery
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Therapy
14.2.2.2. By Surgery
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Therapy
14.3.2.2. By Surgery
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Therapy
14.4.2.2. By Surgery
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Therapy
14.5.2.2. By Surgery
14.5.2.3. By Distribution Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Therapy
14.6.2.2. By Surgery
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Therapy
14.7.2.2. By Surgery
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Therapy
14.8.2.2. By Surgery
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Therapy
14.9.2.2. By Surgery
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Therapy
14.10.2.2. By Surgery
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Therapy
14.11.2.2. By Surgery
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Therapy
14.12.2.2. By Surgery
14.12.2.3. By Distribution Channel
14.13. GCC Countries
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Therapy
14.13.2.2. By Surgery
14.13.2.3. By Distribution Channel
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Therapy
14.14.2.2. By Surgery
14.14.2.3. By Distribution Channel
14.15. Israel
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Therapy
14.15.2.2. By Surgery
14.15.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Therapy
15.3.3. By Surgery
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. GlaxoSmithKline plc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Merck & Co., Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. F. Hoffmann-La Roche Ltd.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Isis Pharmaceuticals, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Eli Lilly and Company
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Novartis AG
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Sanofi
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Johnson and Johnson
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Bayer AG
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Cardium
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Pfizer Inc.
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. AstraZeneca
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.13. Amgen Inc.
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.14. Mylan N.V.
16.1.14.1. Overview
16.1.14.2. Product Portfolio
16.1.14.3. Profitability by Market Segments
16.1.14.4. Sales Footprint
16.1.14.5. Strategy Overview
16.1.14.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast by Region, 2016-2032
Table 02: Global Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 03: Global Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 04: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Table 05: North America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 06: North America Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 07: North America Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 08: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Table 09: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 10: Latin America Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 11: Latin America Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 12: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 14: Europe Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 15: Europe Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 16: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 20: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 22: MEA Market Value (US$ Mn) Forecast by Therapy, 2016-2032
Table 23: MEA Market Value (US$ Mn) Forecast by Surgery, 2016-2032
Table 24: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn) by Therapy, 2022-2032
Figure 02: Global Market Value (US$ Mn) by Surgery, 2022-2032
Figure 03: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 04: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 05: Global Market Value (US$ Mn) Analysis by Region, 2016-2032
Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 08: Global Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 09: Global Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 11: Global Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 14: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 17: Global Market Attractiveness by Therapy, 2022-2032
Figure 18: Global Market Attractiveness by Surgery, 2022-2032
Figure 19: Global Market Attractiveness by Distribution Channel, 2022-2032
Figure 20: Global Market Attractiveness by Region, 2022-2032
Figure 21: North America Market Value (US$ Mn) by Therapy, 2022-2032
Figure 22: North America Market Value (US$ Mn) by Surgery, 2022-2032
Figure 23: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 24: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 31: North America Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 34: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 37: North America Market Attractiveness by Therapy, 2022-2032
Figure 38: North America Market Attractiveness by Surgery, 2022-2032
Figure 39: North America Market Attractiveness by Distribution Channel, 2022-2032
Figure 40: North America Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Market Value (US$ Mn) by Therapy, 2022-2032
Figure 42: Latin America Market Value (US$ Mn) by Surgery, 2022-2032
Figure 43: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 44: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 51: Latin America Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 54: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 57: Latin America Market Attractiveness by Therapy, 2022-2032
Figure 58: Latin America Market Attractiveness by Surgery, 2022-2032
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Latin America Market Attractiveness by Country, 2022-2032
Figure 61: Europe Market Value (US$ Mn) by Therapy, 2022-2032
Figure 62: Europe Market Value (US$ Mn) by Surgery, 2022-2032
Figure 63: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 64: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 71: Europe Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 74: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 77: Europe Market Attractiveness by Therapy, 2022-2032
Figure 78: Europe Market Attractiveness by Surgery, 2022-2032
Figure 79: Europe Market Attractiveness by Distribution Channel, 2022-2032
Figure 80: Europe Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Market Value (US$ Mn) by Therapy, 2022-2032
Figure 82: Asia Pacific Market Value (US$ Mn) by Surgery, 2022-2032
Figure 83: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 97: Asia Pacific Market Attractiveness by Therapy, 2022-2032
Figure 98: Asia Pacific Market Attractiveness by Surgery, 2022-2032
Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2022-2032
Figure 100: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 101: MEA Market Value (US$ Mn) by Therapy, 2022-2032
Figure 102: MEA Market Value (US$ Mn) by Surgery, 2022-2032
Figure 103: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 104: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Market Value (US$ Mn) Analysis by Therapy, 2016-2032
Figure 109: MEA Market Value Share (%) and BPS Analysis by Therapy, 2022-2032
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 111: MEA Market Value (US$ Mn) Analysis by Surgery, 2016-2032
Figure 112: MEA Market Value Share (%) and BPS Analysis by Surgery, 2022-2032
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032
Figure 114: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032
Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 117: MEA Market Attractiveness by Therapy, 2022-2032
Figure 118: MEA Market Attractiveness by Surgery, 2022-2032
Figure 119: MEA Market Attractiveness by Distribution Channel, 2022-2032
Figure 120: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
